- Home
- VINP vs ORIC Comparison
VINP vs ORIC Comparison
Compare VINP & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | ORIC |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 1.4B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VINP | ORIC |
|---|---|---|
| Price | $9.47 | $12.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $14.00 | ★ $19.73 |
| AVG Volume (30 Days) | 43.5K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.19 | $7.23 |
| 52 Week High | $13.61 | $14.93 |
Technical Indicators
Market Signals| Indicator | VINP | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 41.69 |
| Support Level | $9.40 | $10.67 |
| Resistance Level | $10.26 | $12.57 |
| Average True Range (ATR) | 0.30 | 0.60 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 39.19 | 0.84 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.